Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Prostate Cancer

Free Subscription Articles published in J Clin Oncol Retrieve available abstracts of 131 articles: HTML format Text format

Single Articles

June 2018
1. REN C, Han C, Wang D, Chen H, et al
   Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: Is Real Circulating Tumor Cell Number Superior to Prostate-Specific Antigen?
   J Clin Oncol. 2018 Jun 12:JCO2018781401. doi: 10.1200/JCO.2018.78.1401.
   PubMed     Text format    
   
   
   
2. BIBAULT JE, Blanchard P
   Treating Metastatic Prostate Cancer With Local Therapies: Is It Still Wishful Thinking?
   J Clin Oncol. 2018 Jun 1:JCO2017775429. doi: 10.1200/JCO.2017.77.5429.
   PubMed     Text format    
   
   
   
3. CATTRINI C, Zanardi E, Boccardo F
   Androgen-Deprivation Therapy Is More Than Palliation in Oligometastatic Prostate Cancer.
   J Clin Oncol. 2018 Jun 1:JCO2018780031. doi: 10.1200/JCO.2018.78.0031.
   PubMed     Text format    
   
   
   May 2018
4. SPRATT DE, Carroll PR
   Optimal Radical Therapy for Localized Prostate Cancer: Recreation of the Self-Fulfilling Prophecy With Combination Brachytherapy?
   J Clin Oncol. 2018 May 21:JCO2018786236. doi: 10.1200/JCO.2018.78.6236.
   PubMed     Text format    
   
   
   
5. BEKELMAN JE
   A Younger Man With Localized Prostate Cancer Asks, "Which Type of Radiation Is Right for Me?"
   J Clin Oncol. 2018 May 2:JCO2018777235. doi: 10.1200/JCO.2018.77.7235.
   PubMed     Text format     Abstract available
   
   
   April 2018
6. JANSSON F, Drevin L, Frisell T, Stattin P, et al
   Concordance of Non-Low-Risk Disease Among Pairs of Brothers With Prostate Cancer.
   J Clin Oncol. 2018 Apr 13:JCO2017766907. doi: 10.1200/JCO.2017.76.6907.
   PubMed     Text format     Abstract available
   
   
   
7. SARTOR O
   Curing More Prostate Cancer: Thinking Through the Options.
   J Clin Oncol. 2018 Apr 6:JCO2018784835. doi: 10.1200/JCO.2018.78.4835.
   PubMed     Text format    
   
   
   
8. HUSSAIN M, Tangen CM, Thompson IM Jr, Swanson GP, et al
   Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921.
   J Clin Oncol. 2018 Apr 6:JCO2017764126. doi: 10.1200/JCO.2017.76.4126.
   PubMed     Text format     Abstract available
   
   
   
9. MORRIS MJ, Rumble RB, Basch E, Hotte SJ, et al
   Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
   J Clin Oncol. 2018 Apr 2:JCO2018780619. doi: 10.1200/JCO.2018.78.0619.
   PubMed     Text format     Abstract available
   
   
   March 2018
10. SZMULEWITZ RZ, Peer CJ, Ibraheem A, Martinez E, et al
    Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2018 Mar 28:JCO2017764381. doi: 10.1200/JCO.2017.76.4381.
    PubMed     Text format     Abstract available
    
    
    
11. PAN HY, Jiang J, Hoffman KE, Tang C, et al
    Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer.
    J Clin Oncol. 2018 Mar 21:JCO2017755371. doi: 10.1200/JCO.2017.75.5371.
    PubMed     Text format     Abstract available
    
    
    
12. MORGANS AK, Chen YH, Sweeney CJ, Jarrard DF, et al
    Quality of Life During Treatment With Chemohormonal Therapy: Analysis of E3805 Chemohormonal Androgen Ablation Randomized Trial in Prostate Cancer.
    J Clin Oncol. 2018 Mar 9:JCO2017753335. doi: 10.1200/JCO.2017.75.3335.
    PubMed     Text format     Abstract available
    
    
    February 2018
13. ENNIS RD, Hu L, Ryemon SN, Lin J, et al
    Brachytherapy-Based Radiotherapy and Radical Prostatectomy Are Associated With Similar Survival in High-Risk Localized Prostate Cancer.
    J Clin Oncol. 2018 Feb 28:JCO2017759134. doi: 10.1200/JCO.2017.75.9134.
    PubMed     Text format     Abstract available
    
    
    
14. CHEN RC
    Challenges of Interpreting Registry Data in Prostate Cancer: Interpreting Retrospective Results Along With or in Absence of Clinical Trial Data.
    J Clin Oncol. 2018 Feb 28:JCO2017775833. doi: 10.1200/JCO.2017.77.5833.
    PubMed     Text format    
    
    
    
15. TSAO CK, Oh WK
    First-Line Treatment of Hormone-Sensitive Metastatic Prostate Cancer: Is There a Single Standard of Care?
    J Clin Oncol. 2018 Feb 12:JCO2017774315. doi: 10.1200/JCO.2017.77.4315.
    PubMed     Text format    
    
    
    
16. FAIENA I, Holden S, Cooperberg MR, Holden S, et al
    Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?
    J Clin Oncol. 2018 Feb 5:JCO2017764050. doi: 10.1200/JCO.2017.76.4050.
    PubMed     Text format    
    
    
    January 2018
17. KYRIAKOPOULOS CE, Chen YH, Carducci MA, Liu G, et al
    Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial.
    J Clin Oncol. 2018 Jan 31:JCO2017753657. doi: 10.1200/JCO.2017.75.3657.
    PubMed     Text format     Abstract available
    
    
    
18. HORIGUCHI M, Uno H, Wei LJ
    Evaluating Noninferiority With Clinically Interpretable Statistics for the PROSELICA Study to Assess Treatment Efficacy of a Reduced Dose of Cabazitaxel for Treating Metastatic Prostate Cancer.
    J Clin Oncol. 2018 Jan 26:JCO2017759829. doi: 10.1200/JCO.2017.75.9829.
    PubMed     Text format    
    
    
    
19. ABIDA W, Sawyers CL
    Targeting DNA Repair in Prostate Cancer.
    J Clin Oncol. 2018 Jan 25:JCO2017766592. doi: 10.1200/JCO.2017.76.6592.
    PubMed     Text format    
    
    
    
20. MORGANS AK
    Optimization of Risk Stratification in Localized Prostate Cancer.
    J Clin Oncol. 2018 Jan 5:JCO2017762971. doi: 10.1200/JCO.2017.76.2971.
    PubMed     Text format     Abstract available
    
    
    December 2017
21. ANTONARAKIS ES
    Circulating Tumor Cell Eradication as an Intermediate Efficacy End Point for Metastatic Castration-Resistant Prostate Cancer: Is There Enough Evidence?
    J Clin Oncol. 2017 Dec 22:JCO2017765487. doi: 10.1200/JCO.2017.76.5487.
    PubMed     Text format    
    
    
    
22. HELLER G, McCormack R, Kheoh T, Molina A, et al
    Circulating Tumor Cell Number as a Response Measure of Prolonged Survival for Metastatic Castration-Resistant Prostate Cancer: A Comparison With Prostate-Specific Antigen Across Five Randomized Phase III Clinical Trials.
    J Clin Oncol. 2017 Dec 22:JCO2017752998. doi: 10.1200/JCO.2017.75.2998.
    PubMed     Text format     Abstract available
    
    
    
23. ZHU Y, Ye D
    Measurement of Metastasis in the Follow-Up of Localized Prostate Cancer.
    J Clin Oncol. 2017 Dec 21:JCO2017762005. doi: 10.1200/JCO.2017.76.2005.
    PubMed     Text format    
    
    
    
24. HARSHMAN LC, Chen YH, Liu G, Carducci MA, et al
    Seven-Month Prostate-Specific Antigen Is Prognostic in Metastatic Hormone Sensitive Prostate Cancer Treated With Androgen Deprivation With Or Without Docetaxel.
    J Clin Oncol. 2017 Dec 20:JCO2017753921. doi: 10.1200/JCO.2017.75.3921.
    PubMed     Text format     Abstract available
    
    
    
25. HUSSAIN M, Daignault-Newton S, Twardowski PW, Albany C, et al
    Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012.
    J Clin Oncol. 2017 Dec 20:JCO2017757310. doi: 10.1200/JCO.2017.75.7310.
    PubMed     Text format     Abstract available
    
    
    
26. PHILLIPS RM, Hayman J, Tran PT
    STOMPing Out Hormone-Sensitive Metastases With Local Therapies in Prostate Cancer.
    J Clin Oncol. 2017 Dec 14:JCO2017765495. doi: 10.1200/JCO.2017.76.5495.
    PubMed     Text format    
    
    
    
27. OST P, Reynders D, Decaestecker K, Fonteyne V, et al
    Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.
    J Clin Oncol. 2017 Dec 14:JCO2017754853. doi: 10.1200/JCO.2017.75.4853.
    PubMed     Text format     Abstract available
    
    
    
28. GIRI VN, Knudsen KE, Kelly WK, Abida W, et al
    Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017.
    J Clin Oncol. 2017 Dec 13:JCO2017741173. doi: 10.1200/JCO.2017.74.1173.
    PubMed     Text format     Abstract available
    
    
    November 2017
29. SPRATT DE, Zhang J, Santiago-Jimenez M, Dess RT, et al
    Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer.
    J Clin Oncol. 2017 Nov 29:JCO2017742940. doi: 10.1200/JCO.2017.74.2940.
    PubMed     Text format     Abstract available
    
    
    October 2017
30. CHEN DY, See LC, Liu JR, Chuang CK, et al
    Risk of Cardiovascular Ischemic Events After Surgical Castration and Gonadotropin-Releasing Hormone Agonist Therapy for Prostate Cancer: A Nationwide Cohort Study.
    J Clin Oncol. 2017 Oct 2:JCO2016714204. doi: 10.1200/JCO.2016.71.4204.
    PubMed     Text format     Abstract available
    
    
    September 2017
31. RAJAN P, Sooriakumaran P, Nyberg T, Akre O, et al
    Effect of Comorbidity on Prostate Cancer-Specific Mortality: A Prospective Observational Study.
    J Clin Oncol. 2017 Sep 20:JCO2016707794. doi: 10.1200/JCO.2016.70.7794.
    PubMed     Text format     Abstract available
    
    
    August 2017
32. BAIK SH, Kury FSP, McDonald CJ
    Risk of Alzheimer's Disease Among Senior Medicare Beneficiaries Treated With Androgen Deprivation Therapy for Prostate Cancer.
    J Clin Oncol. 2017 Aug 25:JCO2017726109. doi: 10.1200/JCO.2017.72.6109.
    PubMed     Text format     Abstract available
    
    
    
33. MUCCI LA, Kantoff PW
    Is the Evidence Sufficient to Recommend Statins for All Men With Prostate Cancer?
    J Clin Oncol. 2017 Aug 17:JCO2017747915. doi: 10.1200/JCO.2017.74.7915.
    PubMed     Text format    
    
    
    
34. EISENBERGER M, Hardy-Bessard AC, Kim CS, Geczi L, et al
    Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m2) and the Currently Approved Dose (25 mg/m2) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA.
    J Clin Oncol. 2017 Aug 15:JCO2016721076. doi: 10.1200/JCO.2016.72.1076.
    PubMed     Text format     Abstract available
    
    
    
35. ZHANG T, Armstrong AJ
    The Who, What, and How of Cabazitaxel Treatment in Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2017 Aug 15:JCO2017747931. doi: 10.1200/JCO.2017.74.7931.
    PubMed     Text format    
    
    
    
36. LARSEN SB, Dehlendorff C, Skriver C, Dalton SO, et al
    Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer.
    J Clin Oncol. 2017 Aug 14:JCO2016718981. doi: 10.1200/JCO.2016.71.8981.
    PubMed     Text format     Abstract available
    
    
    
37. XIE W, Regan MM, Buyse M, Halabi S, et al
    Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer.
    J Clin Oncol. 2017 Aug 10:JCO2017739987. doi: 10.1200/JCO.2017.73.9987.
    PubMed     Text format     Abstract available
    
    
    July 2017
38. OUDARD S, Fizazi K, Sengelov L, Daugaard G, et al
    Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA.
    J Clin Oncol. 2017 Jul 28:JCO2016721068. doi: 10.1200/JCO.2016.72.1068.
    PubMed     Text format     Abstract available
    
    
    June 2017
39. HARMON SA, Perk T, Lin C, Eickhoff J, et al
    Quantitative Assessment of Early [18F]Sodium Fluoride Positron Emission Tomography/Computed Tomography Response to Treatment in Men With Metastatic Prostate Cancer to Bone.
    J Clin Oncol. 2017 Jun 27:JCO2017722348. doi: 10.1200/JCO.2017.72.2348.
    PubMed     Text format     Abstract available
    
    
    
40. ANTONARAKIS ES, Tagawa ST, Galletti G, Worroll D, et al
    Randomized, Noncomparative, Phase II Trial of Early Switch From Docetaxel to Cabazitaxel or Vice Versa, With Integrated Biomarker Analysis, in Men With Chemotherapy-Naive, Metastatic, Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2017 Jun 20:JCO2017724138. doi: 10.1200/JCO.2017.72.4138.
    PubMed     Text format     Abstract available
    
    
    
41. BURRIS HA, Infante JR, Ansell SM, Nemunaitis JJ, et al
    Safety and Activity of Varlilumab, a Novel and First-in-Class Agonist Anti-CD27 Antibody, in Patients With Advanced Solid Tumors.
    J Clin Oncol. 2017;35:2028-2036.
    PubMed     Text format     Abstract available
    
    
    
42. SPRATT DE, Yousefi K, Deheshi S, Ross AE, et al
    Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease.
    J Clin Oncol. 2017;35:1991-1998.
    PubMed     Text format     Abstract available
    
    
    May 2017
43. HOFFMAN RM, Lo M, Clark JA, Albertsen PC, et al
    Treatment Decision Regret Among Long-Term Survivors of Localized Prostate Cancer: Results From the Prostate Cancer Outcomes Study.
    J Clin Oncol. 2017 May 11:JCO2016706317. doi: 10.1200/JCO.2016.70.6317.
    PubMed     Text format     Abstract available
    
    
    
44. PARIKH RR, Kim IY
    Can Genomic Data Guide the Postoperative Management of Prostate Cancer?
    J Clin Oncol. 2017 May 4:JCO2017724849. doi: 10.1200/JCO.2017.72.4849.
    PubMed     Text format    
    
    
    
45. VAN DE WAL M, Thewes B, Gielissen M, Speckens A, et al
    Efficacy of Blended Cognitive Behavior Therapy for High Fear of Recurrence in Breast, Prostate, and Colorectal Cancer Survivors: The SWORD Study, a Randomized Controlled Trial.
    J Clin Oncol. 2017 May 4:JCO2016705301. doi: 10.1200/JCO.2016.70.5301.
    PubMed     Text format     Abstract available
    
    
    
46. LOEB S, Folkvaljon Y, Damber JE, Alukal J, et al
    Testosterone Replacement Therapy and Risk of Favorable and Aggressive Prostate Cancer.
    J Clin Oncol. 2017;35:1430-1436.
    PubMed     Text format     Abstract available
    
    
    April 2017
47. LECARPENTIER J, Silvestri V, Kuchenbaecker KB, Barrowdale D, et al
    Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores.
    J Clin Oncol. 2017 Apr 27:JCO2016694935. doi: 10.1200/JCO.2016.69.4935.
    PubMed     Text format     Abstract available
    
    
    
48. VIRGO KS, Basch E, Loblaw DA, Oliver T, et al
    Second-Line Hormonal Therapy for Men With Chemotherapy-Naive, Castration-Resistant Prostate Cancer: American Society of Clinical Oncology Provisional Clinical Opinion.
    J Clin Oncol. 2017 Apr 25:JCO2017728030. doi: 10.1200/JCO.2017.72.8030.
    PubMed     Text format     Abstract available
    
    
    
49. PERNAR CH, Downer MK, Wilson KM, Stampfer MJ, et al
    Vasectomy and Risk of Prostate Cancer: How to Weigh Current Evidence.
    J Clin Oncol. 2017;35:1272-1273.
    PubMed     Text format    
    
    
    
50. BUBLEY GJ, Balk SP
    Association Between Androgen Receptor Splice Variants and Prostate Cancer Resistance to Abiraterone and Enzalutamide.
    J Clin Oncol. 2017 Apr 17:JCO2017728808. doi: 10.1200/JCO.2017.72.8808.
    PubMed     Text format    
    
    
    
51. ANTONARAKIS ES, Lu C, Luber B, Wang H, et al
    Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.
    J Clin Oncol. 2017 Apr 6:JCO2016701961. doi: 10.1200/JCO.2016.70.1961.
    PubMed     Text format     Abstract available
    
    
    March 2017
52. YU JB
    Hypofractionated Radiotherapy for Prostate Cancer: Further Evidence to Tip the Scales.
    J Clin Oncol. 2017 Mar 29:JCO2017727016. doi: 10.1200/JCO.2017.72.7016.
    PubMed     Text format    
    
    
    
53. ARCANGELI G, Saracino B, Arcangeli S, Gomellini S, et al
    Moderate Hypofractionation in High-Risk, Organ-Confined Prostate Cancer: Final Results of a Phase III Randomized Trial.
    J Clin Oncol. 2017 Mar 29:JCO2016704189. doi: 10.1200/JCO.2016.70.4189.
    PubMed     Text format     Abstract available
    
    
    
54. DALELA D, Santiago-Jimenez M, Yousefi K, Karnes RJ, et al
    Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model.
    J Clin Oncol. 2017 Mar 28:JCO2016699918. doi: 10.1200/JCO.2016.69.9918.
    PubMed     Text format     Abstract available
    
    
    
55. GARZOTTO M
    Is Low-Risk Prostate Cancer More Indolent in Younger Patients?
    J Clin Oncol. 2017 Mar 27:JCO2017723684. doi: 10.1200/JCO.2017.72.3684.
    PubMed     Text format    
    
    
    
56. LEAPMAN MS, Cowan JE, Nguyen HG, Shinohara KK, et al
    Active Surveillance in Younger Men With Prostate Cancer.
    J Clin Oncol. 2017 Mar 27:JCO2016680058. doi: 10.1200/JCO.2016.68.0058.
    PubMed     Text format     Abstract available
    
    
    
57. CHIN J, Rumble RB, Kollmeier M, Heath E, et al
    Brachytherapy for Patients With Prostate Cancer: American Society of Clinical Oncology/Cancer Care Ontario Joint Guideline Update.
    J Clin Oncol. 2017 Mar 27:JCO2016720466. doi: 10.1200/JCO.2016.72.0466.
    PubMed     Text format     Abstract available
    
    
    
58. CATTON CN, Lukka H, Gu CS, Martin JM, et al
    Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer.
    J Clin Oncol. 2017 Mar 15:JCO2016717397. doi: 10.1200/JCO.2016.71.7397.
    PubMed     Text format     Abstract available
    
    
    
59. MASON MD, Clarke NW, James ND, Dearnaley DP, et al
    Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naive Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.
    J Clin Oncol. 2017 Mar 13:JCO2016690677. doi: 10.1200/JCO.2016.69.0677.
    PubMed     Text format     Abstract available
    
    
    
60. SAAD F
    Bone-Targeted Therapy in Prostate Cancer in 2017: Lost Opportunities, Confusion, and Controversy.
    J Clin Oncol. 2017 Mar 13:JCO2017722793. doi: 10.1200/JCO.2017.72.2793.
    PubMed     Text format    
    
    
    
61. SMITH BYRNE K, Castano JM, Chirlaque MD, Lilja H, et al
    Vasectomy and Prostate Cancer Risk in the European Prospective Investigation Into Cancer and Nutrition (EPIC).
    J Clin Oncol. 2017 Mar 6:JCO2016700062. doi: 10.1200/JCO.2016.70.0062.
    PubMed     Text format     Abstract available
    
    
    February 2017
62. D'AMICO AV
    Active Surveillance Versus Treatment of Prostate Cancer: Should Metastasis Be the Primary End Point?
    J Clin Oncol. 2017 Feb 27:JCO2016709527. doi: 10.1200/JCO.2016.70.9527.
    PubMed     Text format    
    
    
    January 2017
63. BEER TM, Kwon ED, Drake CG, Fizazi K, et al
    Randomized, Double-Blind, Phase III Trial of Ipilimumab Versus Placebo in Asymptomatic or Minimally Symptomatic Patients With Metastatic Chemotherapy-Naive Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2017;35:40-47.
    PubMed     Text format     Abstract available
    
    
    
64. SENDUR MA, Yalcin B
    Does Enzalutamide Really Reduce the Risk of Progression Compared With Bicalutamide in Patients With Castration-Resistant Prostate Cancer?
    J Clin Oncol. 2017;35:122.
    PubMed     Text format    
    
    
    
65. MICHELS J
    Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial-There is No Significant Reduction in Death (Yet).
    J Clin Oncol. 2017;35:123.
    PubMed     Text format    
    
    
    
66. KIM W, Fong L
    Can Prostate Cancer Really Respond to Immunotherapy?
    J Clin Oncol. 2017;35:4-5.
    PubMed     Text format    
    
    
    December 2016
67. TOSOIAN JJ, Carter HB
    Active Surveillance of Localized Prostate Cancer: Acknowledging Uncertainty.
    J Clin Oncol. 2016;34:4452.
    PubMed     Text format    
    
    
    
68. ALBERTSEN PC
    Risk Factors for Prostate Cancer: Which Are Truly Predictive of Clinically Significant Disease?
    J Clin Oncol. 2016;34:4310-4311.
    PubMed     Text format    
    
    
    
69. TANGEN CM, Goodman PJ, Till C, Schenk JM, et al
    Biases in Recommendations for and Acceptance of Prostate Biopsy Significantly Affect Assessment of Prostate Cancer Risk Factors: Results From Two Large Randomized Clinical Trials.
    J Clin Oncol. 2016;34:4338-4344.
    PubMed     Text format     Abstract available
    
    
    November 2016
70. CHAMBERS SK, Occhipinti S, Foley E, Clutton S, et al
    Mindfulness-Based Cognitive Therapy in Advanced Prostate Cancer: A Randomized Controlled Trial.
    J Clin Oncol. 2016 Nov 21:JCO2016688788.
    PubMed     Text format     Abstract available
    
    
    
71. KHOSROW-KHAVAR F, Rej S, Yin H, Aprikian A, et al
    Androgen Deprivation Therapy and the Risk of Dementia in Patients With Prostate Cancer.
    J Clin Oncol. 2016 Nov 21:JCO2016696203.
    PubMed     Text format     Abstract available
    
    
    September 2016
72. KANTOFF PW, Gulley JL, Pico-Navarro C
    Revised Overall Survival Analysis of a Phase II, Randomized, Double-Blind, Controlled Study of PROSTVAC in Men With Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2016 Sep 19. pii: JCO697748.
    PubMed     Text format    
    
    
    
73. JACOBS EJ, Anderson RL, Stevens VL, Newton CC, et al
    Vasectomy and Prostate Cancer Incidence and Mortality in a Large US Cohort.
    J Clin Oncol. 2016 Sep 19. pii: JCO662361.
    PubMed     Text format     Abstract available
    
    
    
74. DU J, Yan W, Mai Z
    Dose-Escalated External-Beam Radiotherapy for Prostate Cancer: Two Ensuing Questions.
    J Clin Oncol. 2016 Sep 12. pii: JCO685859.
    PubMed     Text format    
    
    
    
75. GIACALONE NJ, Wu J, Chen MH, Renshaw A, et al
    Prostate-Specific Antigen Failure and Risk of Death Within Comorbidity Subgroups Among Men With Unfavorable-Risk Prostate Cancer Treated in a Randomized Trial.
    J Clin Oncol. 2016 Sep 6. pii: JCO684530.
    PubMed     Text format     Abstract available
    
    
    August 2016
76. ZUMSTEG ZS, Daskivich TJ, Sandler HM
    Salvage Radiotherapy for Biochemically Recurrent Prostate Cancer After Prostatectomy.
    J Clin Oncol. 2016 Aug 29. pii: JCO692509.
    PubMed     Text format     Abstract available
    
    
    
77. STISH BJ, Pisansky TM, Harmsen WS, Davis BJ, et al
    Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer.
    J Clin Oncol. 2016 Aug 1. pii: JCO683425.
    PubMed     Text format     Abstract available
    
    
    July 2016
78. ROCA E, Valcamonico F, Amoroso V, Antonelli A, et al
    Serum Vitamin D and Prostate Cancer Prognosis: The Story Continues.
    J Clin Oncol. 2016 Jul 25. pii: JCO682617.
    PubMed     Text format    
    
    
    
79. MITTAKANTI HR, Thomas IC, Chung BI, Sonn GA, et al
    Accuracy of Prostate-Specific Antigen Values in Prostate Cancer Registries.
    J Clin Oncol. 2016 Jul 25. pii: JCO689216.
    PubMed     Text format    
    
    
    
80. LOGOTHETIS CJ, Aparicio AM
    Is It Time to Re-Examine the Prostate Cancer Treatment Paradigm by Targeting the Interaction Between the Prostate and Metastases?
    J Clin Oncol. 2016 Jul 18. pii: JCO684738.
    PubMed     Text format    
    
    
    
81. PENSON DF, Resnick MJ
    Let's Not Throw the Baby out With the Bathwater in Prostate Cancer Screening.
    J Clin Oncol. 2016 Jul 18. pii: JCO687194.
    PubMed     Text format    
    
    
    
82. SMITH M, De Bono J, Sternberg C, Le Moulec S, et al
    Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.
    J Clin Oncol. 2016 Jul 11. pii: JCO655597.
    PubMed     Text format     Abstract available
    
    
    
83. ALUMKAL JJ, Beer TM
    Raising the Bar for Therapeutic Trials in Advanced Prostate Cancer.
    J Clin Oncol. 2016 Jul 11. pii: JCO680439.
    PubMed     Text format    
    
    
    June 2016
84. RUSTHOVEN CG, Jones BL, Flaig TW, Crawford ED, et al
    Improved Survival With Prostate Radiation in Addition to Androgen Deprivation Therapy for Men With Newly Diagnosed Metastatic Prostate Cancer.
    J Clin Oncol. 2016 Jun 20. pii: JCO674788.
    PubMed     Text format     Abstract available
    
    
    
85. LOEB S
    Evidence-Based Versus Personalized Prostate Cancer Screening: Using Baseline Prostate-Specific Antigen Measurements to Individualize Screening.
    J Clin Oncol. 2016 Jun 20. pii: JCO682138.
    PubMed     Text format    
    
    
    
86. STERNBERG C, Armstrong A, Pili R, Ng S, et al
    Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer.
    J Clin Oncol. 2016 Jun 13. pii: JCO669697.
    PubMed     Text format     Abstract available
    
    
    
87. PRESTON MA, Batista JL, Wilson KM, Carlsson SV, et al
    Baseline Prostate-Specific Antigen Levels in Midlife Predict Lethal Prostate Cancer.
    J Clin Oncol. 2016 Jun 13. pii: JCO667527.
    PubMed     Text format     Abstract available
    
    
    April 2016
88. NYAME YA, Murphy AB, Bowen DK, Jordan G, et al
    Associations Between Serum Vitamin D and Adverse Pathology in Men Undergoing Radical Prostatectomy.
    J Clin Oncol. 2016;34:1345-9.
    PubMed     Text format     Abstract available
    
    
    
89. ZIETMAN AL
    Making Radiation Therapy for Prostate Cancer More Economical and More Convenient.
    J Clin Oncol. 2016 Apr 18. pii: JCO673764.
    PubMed     Text format    
    
    
    
90. DINH KT, Reznor G, Muralidhar V, Mahal BA, et al
    Association of Androgen Deprivation Therapy With Depression in Localized Prostate Cancer.
    J Clin Oncol. 2016 Apr 11. pii: JCO641969.
    PubMed     Text format     Abstract available
    
    
    
91. SCHOLZ MC, Lam RY, Turner JS
    Query About the Frequency of Biopsy Complications.
    J Clin Oncol. 2016;34:1284.
    PubMed     Text format    
    
    
    
92. D'AMICO AV
    Reply to M.C. Scholz et al.
    J Clin Oncol. 2016;34:1284.
    PubMed     Text format    
    
    
    
93. CARTER HB
    Reply to M.C. Scholz et al.
    J Clin Oncol. 2016;34:1284.
    PubMed     Text format    
    
    
    
94. CARMONA R, Zakeri K, Green G, Hwang L, et al
    Improved Method to Stratify Elderly Patients With Cancer at Risk for Competing Events.
    J Clin Oncol. 2016;34:1270-7.
    PubMed     Text format     Abstract available
    
    
    
95. LEE WR, Dignam JJ, Amin MB, Bruner DW, et al
    Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer.
    J Clin Oncol. 2016 Apr 4. pii: JCO670448.
    PubMed     Text format     Abstract available
    
    
    
96. MCKAY RR, Zurita AJ, Werner L, Bruce JY, et al
    A Randomized Phase II Trial of Short-Course Androgen Deprivation Therapy With or Without Bevacizumab for Patients With Recurrent Prostate Cancer After Definitive Local Therapy.
    J Clin Oncol. 2016 Apr 4. pii: JCO653154.
    PubMed     Text format     Abstract available
    
    
    March 2016
97. STEIN MN, Jang TL
    Striving Toward a Cure for Prostate Cancer.
    J Clin Oncol. 2016 Mar 28. pii: JCO663146.
    PubMed     Text format    
    
    
    
98. DOSORETZ AP, Yu JB
    Incorporating Androgen Deprivation With Dose-Escalated External-Beam Radiotherapy for Prostate Cancer.
    J Clin Oncol. 2016 Mar 21. pii: JCO663237.
    PubMed     Text format     Abstract available
    
    
    
99. POLLACK A, Abramowitz MC
    Weighing the Addition of Androgen Suppression Therapy to Radiotherapy Dose Escalation for Intermediate-Risk Prostate Cancer.
    J Clin Oncol. 2016 Mar 14. pii: JCO662320.
    PubMed     Text format    
    
    
    
100. BOLLA M, Maingon P, Carrie C, Villa S, et al
     Short Androgen Suppression and Radiation Dose Escalation for Intermediate- and High-Risk Localized Prostate Cancer: Results of EORTC Trial 22991.
     J Clin Oncol. 2016 Mar 14. pii: JCO648055.
     PubMed     Text format     Abstract available
     
     
     
101. HALABI S, Kelly WK, Ma H, Zhou H, et al
     Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
     J Clin Oncol. 2016 Mar 7. pii: JCO657270.
     PubMed     Text format     Abstract available
     
     
     February 2016
102. SCHER HI, Morris MJ, Stadler WM, Higano C, et al
     Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
     J Clin Oncol. 2016 Feb 22. pii: JCO642702.
     PubMed     Text format     Abstract available
     
     
     
103. MCGINTY HL
     Unlocking Electronic Medical Record Data to Identify Possible Connections Between Cancer and Cognitive Declines.
     J Clin Oncol. 2016;34:530-2.
     PubMed     Text format    
     
     
     
104. NEAD KT, Gaskin G, Chester C, Swisher-McClure S, et al
     Androgen Deprivation Therapy and Future Alzheimer's Disease Risk.
     J Clin Oncol. 2016;34:566-71.
     PubMed     Text format     Abstract available
     
     
     
105. CHEN RC, Rumble RB, Loblaw DA, Finelli A, et al
     Active Surveillance for the Management of Localized Prostate Cancer (Cancer Care Ontario Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.
     J Clin Oncol. 2016 Feb 16. pii: JCO657759.
     PubMed     Text format     Abstract available
     
     
     
106. SCHER HI, Heller G, Molina A, Kheoh T, et al
     Reply to A. Addeo and A. Bahl.
     J Clin Oncol. 2016;34:387-8.
     PubMed     Text format    
     
     
     January 2016
107. PENSON DF, Armstrong AJ, Concepcion R, Agarwal N, et al
     Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.
     J Clin Oncol. 2016 Jan 25. pii: JCO649285.
     PubMed     Text format     Abstract available
     
     
     
108. HUSSAIN M, Tangen C, Higano C, Vogelzang N, et al
     Evaluating Intermittent Androgen-Deprivation Therapy Phase III Clinical Trials: The Devil Is in the Details.
     J Clin Oncol. 2016;34:280-5.
     PubMed     Text format     Abstract available
     
     
     
109. DEAL AM, Williams GR, Guerard EJ, Pergolotti M, et al
     Physical activity communication between oncology providers and patients with early stage breast, colon or prostate cancer.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
110. LEONG N, Hodgson S, Wambolt E, Hildebrand C, et al
     Development and evaluation of the TrueNTH-Prostate Cancer Canada electronic Library for Improved (urinary and bowel) Function post Treatment (TrueNTH-PCC-eLIFT).
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
111. ZAROWSKI C, Dayan M, Pollock P, Elliott S, et al
     Utilization of sexual health and pelvic floor physiotherapy services in Vancouver's Prostate Cancer Supportive Care (PCSC) Program.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
112. BORSCH C, Garg B, Dobek JC, Doggett R, et al
     Falls and frailty in prostate cancer survivors on androgen deprivation therapy.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
113. POLLOCK P, Wassersug RJ, Zarowski C, Dayan M, et al
     Successful implementation of a disease-specific survivorship program for men with prostate cancer (PC) and their partners.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
114. LIN DW, Karsh LI, Shevrin DH, Shore ND, et al
     The TRUMPET registry: Assessing clinical outcomes and quality of life in patients with castration-resistant prostate cancer and their caregivers.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
115. FRANKLAND J, Brodie H, Cooke D, Pickering R, et al
     The True NTH Prostate Cancer Survivorship Care programme: Development and evaluation of a model for delivering follow-up care to men with prostate cancer.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
116. 
     Thoughts and experience 10 years post surgery from a cancer researcher and survivor: The burdens of a prostate cancer survivor.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
117. MAY S, Feller JF
     Transrectal MR-guided laser focal therapy of recurrent prostate cancer in a patient post-proton therapy: A case study.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
118. PORTER KR, Slezak JM, Chien GW, Jacobsen SJ, et al
     Racial and ethnic variation in baseline health-related quality of life scores prior to prostate cancer treatment.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
119. DU L, Ahmed IA, Morgans AK
     Education practices in prostate cancer: A comparison of patient and caregiver experiences.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
120. TSANG V, Palmer-Hague JL, Wassersug RJ, Nasiopoulos E, et al
     Using eye-tracking to quantify the impact of prostate cancer treatments on male libido: A pilot study.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
121. NEWTON RU, Culos-Reed SN, Faithfull S, Lambert S, et al
     An international, population-level initiative to promote healthy lifestyle practices among prostate cancer survivors.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
122. MALLAPAREDDI A, Ruterbusch J, Reamer E, Eggly S, et al
     Active surveillance for early stage prostate cancer: What do men and their partners think?
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
123. GRANDE D, Crossette L, Bekelman JE, Pollack CE, et al
     Understanding the impact of primary care providers on treatment decisions for men with localized prostate cancer.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     
124. BIDDLE H, Hunnicutt BA, Trenkner S
     SEASONS: A prospective study assessing the physical, psychosocial, spiritual, and financial needs of patients with breast and prostate cancer.
     J Clin Oncol. 2016;34.
     PubMed     Text format     Abstract available
     
     
     December 2015
125. WANG X, Harshman LC, Xie W, Nakabayashi M, et al
     Association of SLCO2B1 Genotypes With Time to Progression and Overall Survival in Patients Receiving Androgen-Deprivation Therapy for Prostate Cancer.
     J Clin Oncol. 2015 Dec 14. pii: JCO625988.
     PubMed     Text format     Abstract available
     
     
     November 2015
126. PARK JC, Eisenberger MA
     Intermittent Androgen Deprivation in Prostate Cancer: Are We Ready to Quit?
     J Clin Oncol. 2015 Nov 30. pii: JCO641019.
     PubMed     Text format    
     
     
     
127. ADDEO A, Bahl A
     Do All High- and Intermediate-Risk Patients With Metastatic Castration-Resistant Prostate Cancer Really Benefit From Abiraterone?
     J Clin Oncol. 2015 Nov 23. pii: JCO628537.
     PubMed     Text format    
     
     
     
128. MURPHY DR, Wu L, Thomas EJ, Forjuoh SN, et al
     Electronic Trigger-Based Intervention to Reduce Delays in Diagnostic Evaluation for Cancer: A Cluster Randomized Controlled Trial.
     J Clin Oncol. 2015;33:3560-7.
     PubMed     Text format     Abstract available
     
     
     October 2015
129. LU K
     The Negative Is Not So Negative: What Do We Learn From Trials With Orteronel?
     J Clin Oncol. 2015;33:3221.
     PubMed     Text format    
     
     
     
130. FIZAZI K, Dreicer R
     Reply to K. Lu.
     J Clin Oncol. 2015;33:3222.
     PubMed     Text format    
     
     
     
131. MORRIS MJ
     Reply to K. Lu.
     J Clin Oncol. 2015;33:3222-3.
     PubMed     Text format    
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: